Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor.
The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission.
Get the full story on our sister site, Drug Delivery Business.